Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomized, Open-label Phase II Trial Testing the Activity of XL092 (Zanzalintinib) in Patients With Advanced Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

NCT06571734 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT06571734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06571734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomized, Open-label Phase II Trial Testing the Activity of XL092 (Zanzalintinib) in Patients With Advanced Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Recruiting
Start date
September 19, 2024
Completion date
July 1, 2033
Enrollment
73 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone sarcoma, ewing sarcoma, ewing sarcoma metastatic, metastatic leiomyosarcoma, osteosarcoma metastatic, sarcoma metastatic, sarcoma of bone, synovial sarcomas, translocation-associated soft tissue sarcoma, unresectable leiomyosarcoma